CLDX: Celldex Therapeutics Inc Price to Sales
Celldex Therapeutics (CLDX) is developing targeted inflammation therapies in collaboration with medical centers. Monitoring the company's P/S ratio captures its market value relative to revenue, where 13951.10 determines the current status of this parameter. Price action depends on barzolvolimab trials and R&D expenditures. Production stability is ensured by strict cold chain controls and the diversification of international biomaterial suppliers.
Metric breakdowns and analytics for Celldex (CLDX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
CLDX - Net Income|Expected Net Income Celldex Therapeutics|CLDX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Celldex Therapeutics Inc|CLDX - PEG Multiple|Business Value to Operating Income Before Depreciation Celldex|CLDX - Operating profit EBITDA|Net earnings per one share for the last twelve months Celldex Therapeutics|CLDX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months celldex.com|CLDX - Earnings growth in current year|Earnings growth forecast for next year Celldex Therapeutics
- issuer revenue and sales details:
General company analysis:celldex.com (CLDX)
The risk of operating income degradation leaves the business vulnerable to market shocks, yet patent protection for high-margin urticaria therapy antibodies provides Celldex Therapeutics (CLDX) with a significant margin of safety. By analyzing the price-to-sales ratio, an investor determines the market premium paid per unit of revenue, which allows for the distinction between a fundamental undervaluation of the asset and a dangerous value trap during a price decline.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Protagonist Corp (PTGX) - Market Cap to Revenue|IMVT: P/S Multiple|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|Price-to-Revenue Ratio Aurinia Pharma (AUPH)|Price-to-Revenue Ratio BCRX (BioCryst Corp)|P/S Multiple VERA (Vera Therapeutics, Inc.)|DNTH: Market Cap to Revenue Ratio|Pharvaris - P/S Multiple|Price to Sales AbCellera Biologics Inc.|TRML (Tourmaline Corp) - Market Cap to Revenue|Market Cap to Revenue Ratio PGEN|Market Cap to Revenue PHAR|NKTR: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue UPB (Upstream Bio)|Market Cap to Sales Volume ZBIO|P/S Multiple IMNM (Immunome Corp)|Market Capitalization-to-Revenue Ratio GOSS|KalVista Pharmaceuticals - P/S Multiple|Price to Sales septerna.com|Pieris Pharmaceuticals, Inc. (PVLA) - Price-to-Revenue Ratio|Savara Inc - Market Capitalization-to-Revenue Ratio|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|P/S Multiple AnaptysBio Inc.|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN: Price-to-Sales Ratio|P/S Multiple RAPT (RAPT Therapeutics)|Aerovate Therapeutics, Inc. (JBIO) - Price to Sales|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|CABA: Market Cap to Sales Volume|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|P/S Multiple AVTX|Market Cap to Revenue Eledon Pharmaceuticals, Inc ELDN|Price-to-Revenue Ratio Agenus AGEN|Price-to-Revenue Coefficient climbbio.com (CLYM)|Zura Bio - P/S Multiple|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|adagene.com (ADAG) - Price-to-Revenue Ratio|IMA (Ikena Oncology) - Price-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|Market Cap to Revenue Ratio EQ (Equillium Bio)|Market Cap to Revenue CNTB (Connect Biopharma)|immunic-therapeutics.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Atara Bio ATRA|IFRX (InflaRx NV) - Price-to-Sales Ratio|X4 Pharmaceuticals - P/S Multiple|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|CELU: P/S Multiple|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|KZR: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|P/S Multiple Q32 Bio Inc QTTB|GOVX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio EDSA (Edesa Biotech Corp)|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|AIM ImmunoTech Inc. - Market Cap to Revenue|P/S Multiple Aditxt Inc. ADTX|GRI - Price-to-Revenue Ratio|XRTX (XORTX Therapeutics Inc) - Market Cap to Revenue Ratio|HIND: P/S Multiple|Price to Sales Revelation Biosciences Corp (REVB)|INDP (Indaptus Therapeutics) - P/S Multiple|Market Cap to Revenue scinai.com (SCNI)|P/S Multiple CALI|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGMS - Price-to-Revenue Ratio|ITOS: Price-to-Revenue Ratio|OCEA: P/S Multiple|Market Cap to Revenue Ratio TCBP|THRD (Third Harmonic Bio, Inc) - P/S Multiple
